Hematology
Volume 26, 2021 - Issue 1
Open access
2,765
Views
1
CrossRef citations to date
0
Altmetric
Articles
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma
Chor Sang Chima Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pok Fu Lam, Hong KongCorrespondence[email protected]
https://orcid.org/0000-0003-2427-915X
Shaji Kumarb Division of Hematology, Mayo Clinic, Rochester, MN, USA
https://orcid.org/0000-0001-5392-9284
Vincent Kai Chung Wongc Department of Pharmacy, Queen Mary Hospital, Pok Fu Lam, Hong Kong
, Cheong Ngaia Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pok Fu Lam, Hong Kong
https://orcid.org/0000-0002-6438-2170
Yok Lam Kwonga Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pok Fu Lam, Hong Kong
https://orcid.org/0000-0001-8156-6978
Pages 652-655
|
Published online: 03 Sep 2021
Reprints and Permissions
This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.
You are not required to obtain permission to reuse this article in part or whole.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.